SYNGENE - Technical Analysis with Chart Patterns & Indicators
Back to ListTechnical Rating: 2.7
| Stock Code | SYNGENE | Market Cap | 18,741 Cr. | Current Price | 465 ₹ | High / Low | 761 ₹ |
| Stock P/E | 48.9 | Book Value | 115 ₹ | Dividend Yield | 0.27 % | ROCE | 12.8 % |
| ROE | 9.78 % | Face Value | 10.0 ₹ | DMA 50 | 606 ₹ | DMA 200 | 654 ₹ |
| Chg in FII Hold | -1.35 % | Chg in DII Hold | 1.21 % | PAT Qtr | 68.7 Cr. | PAT Prev Qtr | 66.2 Cr. |
| RSI | 9.80 | MACD | -44.9 | Volume | 14,29,518 | Avg Vol 1Wk | 24,46,234 |
| Low price | 458 ₹ | High price | 761 ₹ | PEG Ratio | 37.9 | Debt to equity | 0.07 |
| 52w Index | 2.36 % | Qtr Profit Var | -44.2 % | EPS | 8.22 ₹ | Industry PE | 36.1 |
📈 Chart Patterns & Trend: SYNGENE is trading at 465 ₹, well below both the 50 DMA (606 ₹) and 200 DMA (654 ₹), indicating strong bearish bias. RSI at 9.8 is extremely oversold, suggesting potential for a technical rebound. MACD at -44.9 confirms heavy bearish momentum. Bollinger Bands place price near the lower band, signaling weakness but possible short-term support.
📊 Volume Trends: Current volume (14.3 lakh) is lower than the 1-week average (24.4 lakh), reflecting reduced participation and weak investor sentiment.
🎯 Momentum Signals:
- Price below both 50 DMA and 200 DMA confirms bearish trend.
- RSI extremely oversold, indicating possible short-term bounce.
- MACD negative, reinforcing downward momentum.
💡 Entry Zone: 455–465 ₹ (near recent support).
🚪 Exit Zone: 600–610 ₹ (near 50 DMA resistance).
🔎 Overall Trend: The stock is reversing from highs and currently in a bearish phase. Sustained recovery requires crossing 606–654 ₹ with volume support.
Positive
- DII holdings increased (+1.21%), showing domestic institutional confidence.
- Low debt-to-equity ratio (0.07) reflects financial stability.
- EPS of 8.22 ₹ supports long-term valuation.
Limitation
- Stock trading well below both 50 DMA and 200 DMA, confirming weakness.
- Extremely low RSI (9.8) highlights oversold conditions but also severe weakness.
- High P/E of 48.9 compared to industry PE of 36.1, suggesting overvaluation.
- PEG ratio of 37.9 highlights poor growth-to-valuation balance.
Company Negative News
- Quarterly profit variation declined (-44.2%).
- FII holdings decreased (-1.35%), showing reduced foreign investor confidence.
- Stock price corrected sharply from 761 ₹ to 465 ₹.
Company Positive News
- Quarterly PAT improved slightly from 66.2 Cr. to 68.7 Cr.
- DII support increased, signaling domestic confidence.
- Strong fundamentals with low debt and stable EPS.
Industry
- Industry PE at 36.1 is lower than SYNGENE’s PE, highlighting premium valuation.
- Biotech and pharma sector supported by global demand for research and drug development.
- Peers may offer better valuation, but SYNGENE has niche positioning in contract research.
Conclusion
SYNGENE is in a bearish phase, trading below key moving averages with extremely weak momentum signals. Entry near 455–465 ₹ offers limited risk, while resistance lies at 600–610 ₹. The stock needs stronger volume and a break above 606–654 ₹ to confirm reversal. Long-term fundamentals remain stable, but short-term traders should be cautious until momentum improves.
I can also prepare a comparative snapshot of SYNGENE vs SUNPHARMA to highlight which one offers better near-term trading opportunities.